• HempFusion Wellness (CBD.U) has announced a non-brokered private placement for gross proceeds of US$2,000,000
  • The company will issue 8,000,000 units at a price of $0.25 per unit with proceeds allocated to general working capital and marketing initiatives
  • The offering is expected to close on September 30, 2021
  • HempFusion Wellness, a health & wellness CBD company, distributes its family of brands to 15,000 retail locations across the United States and internationally
  • HempFusion Wellness (CBD.U) opened trading at C$0.215 per share

HempFusion Wellness (CBD.U) has announced a non-brokered private placement for gross proceeds of US$2,000,000.

The company will issue 8,000,000 units at a price of $0.25 per unit.

Each unit is comprised of one common share and one common share purchase warrant. Each purchase warrant will entitle the holder to acquire one additional common share at a price of $0.50 for a period of four years from the closing date of the offering.

The offering is expected on or about September 30, 2021.

Gross proceeds of the placement will be allocated to general working capital and marketing initiatives.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion Wellness Inc. distributes its family of brands, including HempFusion, Probulin Probiotics, Sagely Naturals, and Apothecanna, to approximately 15,000 retail locations across all 50 states of the United States and select international locations. 

HempFusion Wellness (CBD.U) opened trading at C$0.215 per share.

More From The Market Online

Sona Nanotech reveals results from breast cancer study

Sona Nanotech (CSE:SONA) reveals additional results from the triple-negative breast cancer murine model portion of its research study.

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.